NCT00609167 - Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

November 30, 2010

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

bortezomib

"First 33 patients: 1.3 mg/m\^2 IV Days 1, 4, 8 \& 11~Remaining 30 patients: 1.5 mg/m\^2 IV Days 1, 8, 15 \& 22"

DRUG

cyclophosphamide

300mg/m\^2 PO days 1, 8, 15 \& 22

DRUG

dexamethasone

"First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20~Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond"

Trial Locations (2)

85259-5499

Mayo Clinic in Arizona, Scottsdale

M5G 2N9

Princess Margaret Hospital, Toronto